-
公开(公告)号：US20190162737A1
公开(公告)日：2019-05-30
申请号：US16264779
申请日：2019-02-01
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Ulrich Schotten , Vinzent Rolny
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20190154706A1
公开(公告)日：2019-05-23
申请号：US16257770
申请日：2019-01-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
-
公开(公告)号：US20230296630A1
公开(公告)日：2023-09-21
申请号：US18021021
申请日：2021-08-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Peter Kastner , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , David Conen , Michael Kuehne , Stefan Osswald
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/2871 , G01N2800/2814
Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.
-
公开(公告)号：US20230062697A1
公开(公告)日：2023-03-02
申请号：US17821951
申请日：2022-08-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
-
公开(公告)号：US20210239712A1
公开(公告)日：2021-08-05
申请号：US17181390
申请日：2021-02-22
Applicant: Roche Diagnostics Operations, Inc. , Universiteit Maastricht , Academisch Zickenhuis Maastricht
Inventor： Peter Kastner , Andre Ziegler , Ursula-Henrike Wienhues-Thelen , Vinzent Rolny , Manuel Dietrich , Ulrich Schotten
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.
-
Patent Agency Ranking
公开(公告)号：US20210172962A1
公开(公告)日：2021-06-10
申请号：US17172761
申请日：2021-02-10
Applicant: Roche Diagnostics Operations, Inc. , UNIVERSITEIT MAASTRICHT , AKADEMISCH ZIEKENHUIS MAASTRICHT
Inventor： Manuel Dietrich , Peter Kastner , Vinzent Rolny , Ulrich Schotten , Ursula-Henrike Wienhues-Thelen , Andre Ziegler
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.
-
17.发明申请公开(公告)号：US20190353666A1
公开(公告)日：2019-11-21
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
IPC: G01N33/68
Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：US20190279770A1
公开(公告)日：2019-09-12
申请号：US16158754
申请日：2018-10-12
Applicant: Roche Diagnostics Operations, Inc. , Institut Lorrain du Coeur et des Vaisseux Louis Mathieu
Inventor： Dirk Block , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler , Faiez Zannad , Patrick Rossignol
Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US20160169911A1
公开(公告)日：2016-06-16
申请号：US15054255
申请日：2016-02-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hanspeter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
CPC classification number: G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
Abstract translation: 本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。 该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（ 白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白） 从病人。 进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。 该方法还基于至少一种上述标记的水平的测量。
-
公开(公告)号：US20230296623A1
公开(公告)日：2023-09-21
申请号：US18017073
申请日：2021-07-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Torbjoern Omland , Ursula-Henrike Wienhues-Thelen , Andre Ziegler
IPC: G01N33/68 , G01N33/569
CPC classification number: G01N33/6893 , G01N33/56983 , G01N2800/56
Abstract: The present invention relates to a method for predicting the disease severity in a patient with COVID-19, said method comprising a) determining the level of GDF-15 in a sample from the patient with COVID-19, b) comparing the level determined in step a) to a reference, and predicting the disease severity in a patient with COVID-19. Also encompassed are methods for risk stratification, monitoring of the disease progression and the risk prediction for hospital admission in a patient with COVID-19. Furthermore, methods are provided for predicting the need for intensive care, the risk for thrombosis, pulmonary embolism, hypoxia and mortality in a patient with COVID-19.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.023 seconds)
